IR-1061: Near Infrared Fluorescent Dye Workflows

IR-1061 is a hydrophobic near infrared fluorescent dye designed for OTN-NIR imaging and research applications that benefit from reduced tissue autofluorescence. Its value is not limited to strong emission: performance depends on how the compound is dissolved, encapsulated, and introduced into the optical workflow. APExBIO supplies IR-1061 as a research-use compound for investigators developing fluorescent probes, nanosystems, and in vivo imaging assays.

The IR-1061 product page reports the molecular formula C₄₄H₃₄BClF₄S₂ and molecular weight of 749.13. The material is a solid that should remain tightly sealed and desiccated at −20 °C. It is reported to dissolve in DMSO at concentrations of at least 25.65 mg/mL, while ethanol and water are unsuitable solvents. These specifications make solvent exchange and formulation design central experimental decisions rather than minor preparation details.

Setup and principle overview

NIR-II fluorescence imaging is commonly defined across approximately 1000–1700 nm, where lower photon scattering and reduced autofluorescence can improve visualization through tissue. The reference study on rationally designed IR-1061 NIR-II nanosystems identifies an emission peak near 1064 nm and demonstrates why a carrier can be more than a delivery vehicle: it can change the dye’s conformation and usable fluorescence.

In its neat form, IR-1061 is poorly compatible with aqueous biological environments. A practical workflow therefore separates three variables: the DMSO stock, the aqueous carrier or nanoparticle formulation, and the final imaging matrix. Keeping these variables distinct helps researchers determine whether a weak signal comes from insufficient dye, aggregation, precipitation, tissue attenuation, or instrument settings.

For a fluorescent dye for biomedical research, the best first application is usually a controlled phantom or ex vivo comparison. A carrier-screening experiment can then precede animal work. This sequence reduces the risk of interpreting formulation artifacts as biological differences and provides a baseline for a fluorescent dye for in vivo imaging.

Protocol Parameters

• DMSO stock: Prepare a fresh 1 mg/mL IR-1061 stock in anhydrous DMSO, vortex for 30 seconds, and inspect for visible particles before use.
• Solvent exchange: Add the stock gradually into the aqueous carrier while mixing at 500 rpm for 5 minutes; keep the final DMSO fraction at or below 1% v/v for an initial biological screen.
• Loading screen: Compare 0.005, 0.01, and 0.05 mg/mL total IR-1061 in the formulation, incubating each preparation for 30 minutes at 25 °C before fluorescence measurements.
• Storage handling: Keep the dry compound at −20 °C in a tightly sealed, desiccated container; use freshly prepared solutions within 24 hours rather than storing dilute preparations for extended periods.
• Plate-based QC: Dispense 100 µL of each formulation into a low-background microplate, equilibrate for 10 minutes at room temperature, and measure emission with the detector centered near 1064 nm.

These are practical starting conditions for method development, not universal dosing or formulation specifications. Final concentrations, exposure settings, and administration procedures should be established using institutionally approved protocols and appropriate toxicity controls.

Step-by-step workflow for reproducible imaging

1. Define the optical and biological endpoint

Decide whether the experiment requires a simple fluorescence comparison, depth-resolved tissue imaging, vascular mapping, or longitudinal observation. A fluorescent dye for optical imaging may be judged by peak intensity and contrast-to-background ratio, whereas a vascular assay also requires signal persistence, spatial continuity, and resistance to motion artifacts. Establish the endpoint before optimizing loading so that the formulation is not selected on brightness alone.

2. Prepare the dye without forcing aqueous solubility

Bring only the amount needed for the experiment to room temperature, weigh the solid promptly, and dissolve it in DMSO. Because the product information describes IR-1061 as insoluble in ethanol and water, direct dilution into either solvent is likely to produce an unstable suspension or precipitate. Instead, add the DMSO stock slowly to a preformed lipid, polymer, or other compatible carrier under controlled mixing.

Fresh preparation is especially important for dilute solutions. Avoid repeatedly warming and cooling the same stock, and record the preparation time, DMSO percentage, carrier identity, dye concentration, and mixing order. A matched vehicle control containing the same DMSO percentage is essential for separating solvent effects from fluorescence effects.

3. Screen carrier charge and dye loading

The reference work compared liposomes containing differently charged phospholipids and different amounts of IR-1061. Its central practical result was that anionic liposomes showed the strongest encapsulation tendency, whereas cationic liposomes performed worst. The study also found that the dye can occupy a free state or an aggregate state inside liposomes. Increasing the dye content favored aggregation, which reduced fluorescence.

Translate this finding into a small factorial screen rather than a single formulation. For example, compare an anionic, neutral, and cationic carrier at three dye loadings while holding total lipid or polymer concentration constant. Measure fluorescence per mass of dye, not only total well intensity. A formulation that contains more compound but produces a lower normalized signal may be over-loaded.

4. Verify formulation quality before imaging

Inspect every preparation for haze, sediment, or an altered color. If available, pair fluorescence measurements with particle-size and polydispersity testing, but do not rely on particle size alone: a visually uniform preparation can still contain quenched dye aggregates. Record emission spectra or at least a fixed-window intensity measurement from the same volume and plate position.

Run three essential controls: carrier without dye, dye-containing formulation without biological material, and tissue or cells without dye. These controls reveal carrier autofluorescence, spectral bleed-through, and the baseline background of the biological matrix. For deep tissue studies, add an optical phantom or tissue-mimicking layer so that formulations are compared at the intended imaging depth rather than only in a clear solution.

5. Optimize the acquisition rather than compensating with excess dye

Use a detector and filter set appropriate for emission near 1064 nm, then optimize exposure time, excitation power, gain, and frame averaging in that order. Excessive illumination can increase photobleaching or tissue heating, while excessive gain amplifies background. Keep instrument settings fixed across formulations during the primary comparison. If the assay is longitudinal, include a reference standard or a stable control region in every imaging session.

For in vivo work, randomize the imaging order where practical, use the same anatomical positioning, and define a region-of-interest method before collecting the main dataset. Image analysis should report signal-to-background or contrast-to-background alongside raw intensity. This is particularly important for a near infrared fluorescent probe for in vivo imaging because apparent brightness can change with depth, tissue geometry, and detector response.

Key Innovation from the Reference Study

The study by Yu and colleagues did more than package IR-1061 in liposomes. It systematically connected phospholipid charge and dye loading to encapsulation and molecular state. Anionic liposomes provided the best encapsulation among the tested charge classes, while cationic liposomes provided the poorest. Within the confined liposomal environment, low and higher dye contents shifted the balance between free and aggregated IR-1061; aggregation diminished the fluorescence response.

This finding leads to three assay choices. First, include carrier charge as an experimental factor whenever the dye is encapsulated rather than assuming all liposomes are equivalent. Second, optimize fluorescence per unit dye to identify the point before concentration-driven quenching. Third, evaluate signal duration separately from initial brightness. In the study, the optimized IR1061-ALP-N3 formulation produced clear systemic angiography in mice, and long-term imaging retained strong vascular fluorescence for more than 16 hours, according to the published reference. That result supports testing IR-1061 nanosystems for longitudinal vascular imaging, but it should not be interpreted as a validated clinical performance claim.

Advanced applications and comparative advantages

IR-1061 is well suited to a fluorescent dye for molecular imaging workflow when the experimental objective is localization, distribution, or carrier tracking rather than direct biochemical quantification. Its NIR-II emission can support deep-tissue visualization with less background than shorter-wavelength fluorescence, although actual performance depends on tissue depth, detector sensitivity, formulation, and excitation power.

The reference study demonstrated systemic angiography with high spatial resolution and identified potential uses in intraoperative imaging, hemodynamic evaluation, and quantitative assessment of abnormal femoral arteries. These use cases illustrate a comparative advantage over a simple endpoint assay: the same carrier-formulated dye can be evaluated for signal intensity, anatomical continuity, and persistence over time.

Organic small-molecule fluorophores also offer a different development path from inorganic NIR materials. The cited work notes that inorganic probes can raise concerns about slow excretion and retention, while organic dyes can be attractive for biocompatibility-oriented research. This does not remove the need for formulation-specific safety studies, but it explains why IR-1061 is useful as a platform for testing liposomal or polymeric delivery systems.

The article Polystyrene Nanoparticles for Deep In Vivo NIR Imaging with IR-1061 complements the liposome study by applying the same dye to a polystyrene-based carrier, with emphasis on aggregation and stability. The resource Chirality-Dependent Encapsulation of IR-1061 in PLA Polymers for Deep NIR Imaging extends the formulation question into polymer design. Together, these articles reinforce a practical principle: the carrier environment is part of the optical design.

Troubleshooting and optimization tips

Weak or unexpectedly variable fluorescence

First check aggregation, not just the nominal concentration. Reduce dye loading, compare anionic and neutral carriers, and normalize intensity to the amount of IR-1061. Confirm that the detector is configured for the intended NIR-II window and that the optical path is not saturated. If a formulation is bright immediately but declines during handling, compare a freshly prepared aliquot with the stored sample.

Precipitation after dilution

Precipitation commonly indicates an overly rapid solvent exchange, excessive DMSO dilution into water, or an incompatible carrier. Add the stock slowly under mixing, reduce the dye concentration, and test the carrier before introducing biological material. Do not use ethanol or water as the primary solvent for the dry compound because the product information identifies IR-1061 as insoluble in both.

High background or poor contrast

Run no-dye tissue controls and a vehicle control first. Lower detector gain before lowering the dye concentration, and use a shorter exposure if the background is dominated by stray light or motion. If background increases only in vivo, compare matched regions at the same depth and review tissue positioning. A strong total signal is not sufficient if the contrast-to-background ratio is poor.

Short signal duration

Separate chemical instability from biological clearance by measuring the formulation in a cell-free matrix at the same temperature and time points used in the experiment. Protect preparations from unnecessary repeated handling, minimize illumination during setup, and assess whether high loading caused aggregation. If persistence is the endpoint, prioritize a stable, moderately loaded formulation over the brightest initial formulation.

Future outlook

The most actionable future direction is rational control of the carrier environment. The cited evidence supports systematic tuning of charge, available encapsulation space, and IR-1061 loading rather than treating formulation as a fixed step. For researchers developing a near infrared fluorescent dye for deep tissue imaging, this approach can improve reproducibility across phantoms, ex vivo samples, and longitudinal vascular studies.

Future comparisons should preserve the same core controls: fresh DMSO preparation, normalized dye loading, matched vehicle, carrier-only controls, and fixed optical settings. Such discipline will clarify whether improvements arise from better encapsulation, reduced aggregation, greater stability, or simply more favorable instrument conditions. IR-1061 remains intended for scientific research only and is not approved for diagnostic or medical use.